Cargando…
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
Dystrophic epidermolysis bullosa (DEB) is a hereditary skin fragility disorder, characterized by trauma-induced blistering followed by soft tissue fibrosis. One of the most feared complications is the early development of aggressive cutaneous squamous cell carcinomas (SCC). For patients with locally...
Autores principales: | Diociaiuti, Andrea, Steinke, Holger, Nyström, Alexander, Schwieger-Briel, Agnes, Meiss, Frank, Pfannenberg, Christina, Bruckner-Tuderman, Leena, Ruf, Juri, De Vito, Rita, El Hachem, May, Kiritsi, Dimitra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889571/ https://www.ncbi.nlm.nih.gov/pubmed/31796084 http://dx.doi.org/10.1186/s13023-019-1262-7 |
Ejemplares similares
-
Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers
por: Nyström, Alexander, et al.
Publicado: (2021) -
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
por: Nyström, Alexander, et al.
Publicado: (2015) -
Betulin-Based Oleogel to Improve Wound Healing in Dystrophic Epidermolysis Bullosa: A Prospective Controlled Proof-of-Concept Study
por: Schwieger-Briel, Agnes, et al.
Publicado: (2017) -
Newer Treatment Modalities in Epidermolysis Bullosa
por: Bruckner-Tuderman, Leena
Publicado: (2019) -
Mechanism of Oleogel‐S10: A triterpene preparation for the treatment of epidermolysis bullosa
por: Schwieger‐Briel, Agnes, et al.
Publicado: (2019)